An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a long-term safety and tolerability study. REN001 is administered once daily to
subjects with PMM who have previously completed Study REN001-201 or participated in Study
REN001-101 and withdrew from that study due to the COVID-19 pandemic.